The latest release of the Platform — 24.06 — is now available at platform.opentargets.org.

Key points

In addition to our regular data updates:

Users can now customise the associations view to explore evidence for a set list of entities
We have updated our gene burden dataset with version 5 of the AstraZeneca PheWAS Portal and added new evidence for targets associated with prostate cancer
Notable data updates include ChEMBL 34 and the Gene2Phenotype skeletal panel

Key stats

Metric	Count
Targets	63,226
Diseases	28,198
Drugs	18,041
Evidence	17,703,456
Associations	8,079,215

Additional metrics are available on the Open Targets Community.

View associations for a custom list of entities

Our Associations on the Fly view in all target and disease associations pages now allows you to upload a custom list of entities to obtain a tailored associations view. A much requested feature, this will allow users to easily view target-disease evidence for the specific entities they are interested in, and facilitate therapeutic hypothesis building.

Users can upload .txt, .csv, .tsv, .xlsx, and .json files with up to 2,000 rows. The input file data is validated and matched to the entity names in the Platform, so that users can verify the specific results they want displayed.

Once selected, the entities will appear as pinned rows in the Associations on the Fly view. These can be unpinned as users refine their list.

More information on this feature is available in the documentation.

Gene Burden data update

AstraZeneca PheWAS Portal

We have added new data to our Gene Burden widget, which incorporates the results from the aggregation of rare and ultra-rare variants at the gene-level.

How the Open Targets Platform Integrates Gene Burden Analyses

The Open Targets Platform has become the reference repository for associations based on burden tests. We compare the primary sources of gene burden — Genebass, Regeneron, and the AstraZeneca PheWAS Portal — and their contributions to the Open Targets Platform.

Open Targets BlogIrene López Santiago

In particular, we updated the gene burden results from AstraZeneca’s PheWAS Portal, integrating the version 5 release which aggregates the ExWAS results from a cohort of 470,000 individuals, and contains a more robust and better-powered collapsing analysis derived from the UK Biobank. We have also added links to the respective AstraZeneca PheWAS Portal pages.

Thanks to this update, we integrate an additional 9,533 evidence from the PheWAS Portal, for a total of 21,300, practically doubling the number of associations.

Gene burden evidence for prostate cancer

In addition, we have added ancestry-specific gene burden evidence for prostate cancer. Soh et al. used rare coding variants from whole exome sequencing of 798 Black South African men to identify genes significantly associated with prostate cancer.

The study highlighted three genes MTG1, H3C1, MBP for which little is known about their role in prostate cancer.

Soh, P.X.Y., Mmekwa, N., Petersen, D.C. et al. Prostate cancer genetic risk and associated aggressive disease in men of African ancestry. Nat Commun 14, 8037 (2023).

Gene burden widget on the associations page for MTG1. New data from Soh et al. (2023) is the first evidence in the Platform associating this target with prostate cancer.

Update to SCHEMA consortium data

We have expanded the whole exome sequencing data previously integrated from the SCHEMA consortium. In addition to the 10 genes associated with schizophrenia as a result of a meta-analysis, four genes — TRIO, XPO7, HERC1 and SETD1A — showed statistical significance with high pathogenicity score (class I) variants, and we are therefore able to provide direction of effect assessments.

Singh, T., Poterba, T., Curtis, D. et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604, 509–516 (2022).

Other updates

Following community feedback, we have removed categorical burden tests from the data we integrate from Genebass.

Data updates

This release includes a number of data updates, including ChEMBL, Gene2Phenotype, Genomics England PanelApp, COSMIC, EVA, Probes and Drugs.

ChEMBL 34

Released in April, ChEMBL 34 integrates, for the first time, drug approvals from the European Medicines Agency. This includes 882 drugs prior to January 2023, some of which are only authorised by EMA, and therefore gives a more complete picture of drugs on the market.

Eladocagene exuparvovec (tradename Upstaza) is a new drug added to the Platform thanks to the data in ChEMBL 34. A gene therapy first approved in 2022, it is indicated for Aromatic L-Amino Acid Decarboxylase deficiency, a rare disease that leads to developmental issues.

Additionally, ChEMBL now distinguishes antibody-drug conjugates (ADCs) as a separate modality which are now represented in the Open Targets Platform.

Belantamab Mafotodin (tradename Blenrep) is an antibody drug conjugate drug first approved in 2020.

Gene2Phenotype skeletal panel

We introduced a new Gene2Phenotype panel in this release, adding evidence for rare disease genetics. It contributes 328 new disease/target associations between 289 diseases with musculo-skeletal implications and 260 unique targets.

Gene2Phenotype provides high quality curated genetic associations based on literature. Panels are reviewed by consultant clinical geneticists. The skeletal panel is maintained by Andreas Zankl, Professor of Medical Genetics and Genetic Medicine, University of Sydney.

Gene2Phenotype widget: the new skeletal panel brings in the first Gene2Phenotype evidence associating POP1 with anauxetic dysplasia, with a definitive confidence category.

Genomics England PanelApp

The updated PanelApp data from Genomics England provides almost 2,500 more disease target evidence and 13 new disease related gene panels including a panel for acute rhabdomyolysis and a panel for Autoinflammatory disorders.

As usual, please share any comments, questions, or suggestions on the Open Targets Community.